Save up -80% on Reteplase

Note: this is a drug discount program, not an insurance plan.

RX BIN: 015558
RX PCN: HT
Group ID: DDN6600
Card Holder ID: DDN6600

Pharmacists and Patients support.

2018 Price of Reteplase

Retavase vial half-kit

$2605.93

vial

* price without discount in nearest pharmacy. Price may vary.

Claim your free Reteplase discount card

We offer free Reteplase coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Reteplase every time. What are you waiting for? Claim your prescription drug card now!

Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time

Reteplase volume of distribution

About RX24Drugs

Discount Cards 16,000+

Clients Benefit 29%

Total savings $4,735,080

What is Reteplase

Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a “third-generation” thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase – kringle-1, finger, and epidermal growth factor (EGF).

Reteplase mechanism of action

Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.

Dosage forms of Reteplase

FormRouteStrength
Kit
Powder for solutionintravenous10.4 unit
Prescription Generics

false

International Brands

Retavase

Synonyms

t- PA t-plasminogen activator

Manufacturers

EKR Therapeutics, Inc.

CAS number

133652-38-7

UNII

DQA630RIE9

State

liquid

Affected organisms

Humans and other mammals

Indication of Reteplase

For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction

Toxicity of Reteplase

RX24 Drugs Disclaimer: before buying a Reteplase on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.

Get lower price on Reteplase now!